Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analyst consensus is “Moderate Buy”: Of eight analysts covering Sana Biotechnology, five rate it Buy, one Strong Buy, one Hold, and one Sell. The average 12-month price target is $9.60.
• The stock is trading near its 52-week low: Shares opened at $2.44, compared with a 52-week range of $2.22 to $5.49, and were below their 50-day and 200-day moving averages.
• Quarterly results modestly beat estimates: Sana reported a loss of $0.13 per share versus the consensus estimate of a $0.15 loss; analysts expect a full-year loss of $0.72 per share.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.60.

SANA has been the subject of a number of analyst reports. TD Cowen upgraded shares of Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Bank of America decreased their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Finally, Wall Street Zen lowered shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Monday, July 20th.

Institutional Investors Weigh In On Sana Biotechnology

Large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sana Biotechnology during the third quarter worth $45,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Sana Biotechnology by 23.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,622 shares of the company's stock valued at $159,000 after buying an additional 10,332 shares during the last quarter. T3 Companies LLC raised its holdings in shares of Sana Biotechnology by 162.8% in the third quarter. T3 Companies LLC now owns 29,700 shares of the company's stock valued at $87,000 after buying an additional 18,400 shares during the last quarter. Abel Hall LLC acquired a new position in Sana Biotechnology during the 3rd quarter worth about $35,000. Finally, Sequoia Financial Advisors LLC acquired a new position in Sana Biotechnology during the 2nd quarter worth about $54,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Stock Performance

SANA opened at $2.44 on Wednesday. The company has a market cap of $730.44 million, a PE ratio of -3.21 and a beta of 2.30. The stock has a 50-day moving average of $2.98 and a 200-day moving average of $3.38. Sana Biotechnology has a 52-week low of $2.22 and a 52-week high of $5.49.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, research analysts predict that Sana Biotechnology will post -0.72 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company's approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.